Racura Oncology Ltd
Research Racura Oncology Ltd (RAC.AX) on Bullrun: market cap AUD 304.89M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRAC.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 304.89M
- Financial periodFY2026
- Net income-AUD 11.09M
- Free cash flow-AUD 8.25M
Valuation Snapshot
latest market cap is AUD 304.89M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 11.09M | -AUD 8.25M | n/a | -0.06 | AUD 34.29M | n/a | AUD 36.45M |
| FY2025 | n/a | -AUD 4.79M | -AUD 4.57M | n/a | -0.03 | AUD 13.67M | n/a | AUD 16.01M |
| FY2024 | n/a | -AUD 13.82M | -AUD 9.55M | n/a | -0.08 | AUD 17.19M | n/a | AUD 18.31M |
| FY2023 | n/a | -AUD 9.92M | -AUD 10.65M | n/a | -0.06 | AUD 21.52M | n/a | AUD 25.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 304.89M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Racura Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Racura Oncology Ltd's market cap?
Racura Oncology Ltd's market capitalization is AUD 304.89M.
What does Racura Oncology Ltd do?
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025.